Dreyer Scott 4
4 · COLLEGIUM PHARMACEUTICAL, INC · Filed Dec 10, 2025
Insider Transaction Report
Form 4
Dreyer Scott
EVP & Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
2025-12-08$15.90/sh+17,600$279,840→ 121,213 total - Sale
Common Stock
2025-12-08$47.89/sh−11,125$532,771→ 110,088 total - Sale
Common Stock
2025-12-08$48.66/sh−6,475$315,085→ 103,613 total - Exercise/Conversion
Stock Option (Right to Purchase)
2025-12-08−17,600→ 0 totalExercise: $15.90Exp: 2029-01-25→ Common Stock (17,600 underlying)
Footnotes (4)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025.
- [F2]The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.212 to $48.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
- [F3]The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.215 to $49.08, inclusive.
- [F4]The option is fully vested and exercisable.